gdc
PSSGuide_2021
Cervical Cancer

Drugs for Cervical Cancer

Find financial assistance programs available for cervical cancer drugs.

Avastin (bevacizumab) Injection

Drug company: Genentech
866-422-2377

Avastin is a VEGF-specific angiogenesis inhibitor used, in combination with paclitaxel and cisplatin or paclitaxel and topotecan, for the treatment of patients with persistent, recurrent, or metastatic cervical cancer.

Genentech Oncology offers 2 financial assistance programs for patients using Avastin:

Genentech Oncology Co-pay Assistance Program

Eligible patients with private insurance will pay just a $5 copay per prescription or infusion of Avastin, with an annual benefit limit of $25,000. Retroactive requests for assistance will be honored if the prescription was filled within 180 days before enrollment in this program.

Genentech Patient Foundation

This foundation provides Avastin free of charge to uninsured or underinsured patients whose annual household income is less than $150,000 and who meet specific financial criteria.

Hycamtin (topotecan) Injection

Drug company: Novartis
800-245-5356

Hycamtin for injection is a topoisomerase inhibitor used, in combination with cisplatin, for the treatment of patients with stage IVB, recurrent or persistent carcinoma of the cervix.

Novartis Patient Assistance NOW Oncology offers 1 financial assistance program for patients using Hycamtin:

Novartis Patient Assistance Foundation

Patients who are experiencing financial hardship and have limited or no public or private prescription coverage may be able to receive Hycamtin for free through the Novartis Patient Assistance Foundation. To be eligible, the patient must be a US citizen, and have an annual household income of up to $75,000 for 1 person; $100,000 for 2 people; $125,000 for 3 people; $150,000 for 4 people; and up to $25,000 more for each additional person in the household. Eligible patients will receive Hycamtin for free for 1 year, or until prescription drug coverage becomes available to them.

Keytruda (pembrolizumab)

Drug company: Merck
855-257-3932

Keytruda is a PD-1 inhibitor used for the treatment of recurrent or metastatic cervical cancer progressing during or after chemotherapy in patients whose tumors express PD-L1, as determined by an FDA-approved test. Keytruda is also used, in combination with chemotherapy and with or without Avastin, for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1, as determined by an FDAapproved test.

Merck offers 2 financial assistance programs for patients using Keytruda:

Merck Co-pay Assistance Program

Privately insured patients will pay the first $25 of their copay per Keytruda infusion. The maximum benefit per calendar year is $25,000.

Merck Patient Assistance Program

Patients without insurance or drug prescription coverage may be eligible to receive Keytruda at no cost. Eligible patients must have a household income of $64,000 or less for individuals; $87,100 or less for a couple; or $132,000 or less for a family of 4. Patients with insurance, including Medicare Part D, who still have trouble paying for their medicines may request that an exception be made, provided their household income is not above a set limit.

Mvasi (bevacizumab-awwb)

Drug company: Amgen
888-427-7478

Mvasi, a biosimilar to Avastin, is a VEGF inhibitor used, in combination with chemotherapy (with paclitaxel and cisplatin, or with paclitaxel and topotecan), for the treatment of patients with persistent, recurrent, or metastatic cervical cancer.

Amgen Assist 360 offers 2 financial assistance programs for patients who have been prescribed Mvasi:

Amgen FIRST STEP Program

With this program, eligible patients who have private insurance will pay $0 for the first dose of Mvasi and $5 for each subsequent dose, with a maximum annual benefit of $20,000.

Amgen Safety Net Foundation

Patients who have limited or no insurance coverage and patients with Medicare Part D who satisfy the income eligibility requirements, may receive Mvasi for free.

Tivdak (tisotumab vedotin-tftv) Injection

Drug company: Seagen
855-473-2873

Tivdak is a tissue factor-directed antibody and microtubule inhibitor conjugate, used for the treatment of adults with recurrent or metastatic cervical cancer whose disease progressed during or after chemotherapy.

Seagen Secure offers 3 financial assistance programs for patients using Tivdak:

Commercial Out-Of-Pocket Assistance Program

Eligible patients who have private insurance may pay as little as $5 per prescription fill of Tivdak through this program.

Patient Assistance Program

Eligible patients who are uninsured or underinsured may receive Tivdak for up to 1 year at no cost.

Quick Start Program

This program provides a 15-day supply of Tivdak at no cost to patients who experience delays in insurance.

Zirabev (bevacizumab-bvzr)

Drug company: Pfizer
877-744-5675

Zirabev, a biosimilar to Avastin, is a VEGF inhibitor used, in combination with paclitaxel and cisplatin or paclitaxel and topotecan, for the treatment of patients with persistent, recurrent, or metastatic cervical cancer.

Pfizer Oncology Together offers 2 financial assistance programs for patients who have been prescribed Zirabev:

Pfizer Oncology Together Co-Pay Savings Program

This program assists eligible patients with private insurance so that their monthly copay for Zirabev is $0, with a maximum annual benefit of $25,000.

Pfizer Patient Assistance Program

Through this program, patients who are uninsured may qualify to receive Zirabev for free or at a savings. Eligible patients with government insurance may also receive Zirabev for free if they cannot find independent charitable foundation support.

Table. Drugs Prescribed for Cervical Cancer

  • Drug name (generic name)
  • Drug company
  • Indications
  • Patient support services

    Drug name (generic name)
  • Hycamtin (topotecan) Injection
  • Drug company
  • Novartis
  • Indication
  • Treatment of stage IVB, recurrent or persistent carcinoma of the cervix, in combination with cisplatin
  • Patient support services
  • Novartis Patient Assistance Foundation
    800-277-2254

    Drug name (generic name)
  • Keytruda (pembrolizumab)
  • Drug company
  • Merck
  • Indication
  • Treatment of recurrent or metastatic cervical cancer progressing during or after chemotherapy in patients whose tumors express PD-L1, as determined by an FDA-approved test

    Treatment, in combination with chemotherapy and with or without Avastin, in patients with persistent, recurrent, or metastatic cervical cancer whose tumor expresses PD-L1, as determined by an FDA-approved test
  • Patient support services
  • Merck Co-pay Assistance Program
    855-257-3932

    Merck Patient Assistance Program
    800-727-5400

    Drug name (generic name)
  • Mvasi (bevacizumab-awwb)
  • Drug company
  • Amgen
  • Indication
  • Treatment of persistent, recurrent, or metastatic cervical cancer, in combination with chemotherapy
  • Patient support services
  • Amgen FIRST STEP Program
    888-657-8371

    Amgen Safety Net Foundation
    888-762-6436



Share this:

Last modified: March 17, 2022

Report Broken Links

Have you encountered a problem with a URL (link) on this page not working or displaying an error message?

Help us fix it! Report broken links here.

Report Broken Link

Subscribe to CONQUER: the patient voice

Receive timely cancer news & updates, patient stories, and more.


Country
Race or Ethnicity
Gender
Profession or Role
Primary Interest
Other Interests